These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18077522)

  • 1. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
    Juweid ME
    J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
    Terasawa T; Nihashi T; Hotta T; Nagai H
    J Nucl Med; 2008 Jan; 49(1):13-21. PubMed ID: 18077527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
    [No Abstract]   [Full Text] [Related]  

  • 5. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.
    Kasamon YL; Wahl RL
    Curr Opin Oncol; 2008 Mar; 20(2):206-19. PubMed ID: 18300772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
    Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
    Araf S; Montoto S
    Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
    Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
    ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
    Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
    Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
    Svoboda J; Andreadis C; Elstrom R; Chong EA; Downs LH; Berkowitz A; Luger SM; Porter DL; Nasta S; Tsai D; Loren AW; Siegel DL; Glatstein E; Alavi A; Stadtmauer EA; Schuster SJ
    Bone Marrow Transplant; 2006 Aug; 38(3):211-6. PubMed ID: 16770314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET/CT in lymphoma.
    Juweid ME
    Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-deoxy-2-[
    Withofs N; Bonnet C; Hustinx R
    PET Clin; 2024 Oct; 19(4):447-462. PubMed ID: 38945737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET in children with lymphomas.
    Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
    Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma.
    Bennani-Baiti B; Yadav S; Flynt L; Bennani-Baiti N
    J Clin Oncol; 2015 Apr; 33(10):1216-7. PubMed ID: 25691676
    [No Abstract]   [Full Text] [Related]  

  • 20. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.